mAb² ™
mAb² ™ antibodies are full IgG antibodies with two additional binding sites engineered into the CH3 domains. Depending on the type of additional binding sites assigned to the CH3 domains of the IgG molecule, a number of exciting and completely new therapeutic applications become possible.
Examples include:
- Dual targeting (additional binding sites to a second disease antigen)
- Tissue targeting (additional binding site to tissue or disease -specific markers, transporting the antibody to the site of action)
- New or enhanced effector function
- Oligovalence (additional binding sites to the same disease antigen)
All these applications have one objective: making therapeutic antibodies even more effective in treating patients with high unmet medical need.